Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiovascular Risk Management and Hepatitis C: Combining Drugs
Elise J. Smolders, Peter G. J. ter Horst, Sharon Wolters, et al.
Clinical Pharmacokinetics (2018) Vol. 58, Iss. 5, pp. 565-592
Open Access | Times Cited: 20

Showing 20 citing articles:

Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update
Elise J. Smolders, Anouk M E Jansen, Peter G. J. ter Horst, et al.
Clinical Pharmacokinetics (2019) Vol. 58, Iss. 10, pp. 1237-1263
Open Access | Times Cited: 72
Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications
Lisa Sandmann, Benjamin Schulte, Michael P. Manns, et al.
Visceral Medicine (2019) Vol. 35, Iss. 3, pp. 161-170
Open Access | Times Cited: 69
Outcomes of the Treatment with Glecaprevir/Pibrentasvir following heart transplantation utilizing hepatitis C viremic donors
Alex Reyentovich, C. Gidea, Deane E. Smith, et al.
Clinical Transplantation (2020) Vol. 34, Iss. 9
Closed Access | Times Cited: 26
Hepatitis C virus infection and tight junction proteins: The ties that bind
Laurent Mailly, Thomas F. Baumert
Biochimica et Biophysica Acta (BBA) - Biomembranes (2020) Vol. 1862, Iss. 7, pp. 183296-183296
Open Access | Times Cited: 24
Comorbidities and Contraindicated Medications in Patients with Chronic Hepatitis C Infection in Japan: a Real-World Database Study
Takeya Tsutsumi, Hiroshi Yotsuyanagi
Kanzo (2024) Vol. 65, Iss. 8, pp. 368-390
Open Access | Times Cited: 2
New Antiviral Agents for Treatment of Hepatitis C
Robert Egerman
Clinical Obstetrics & Gynecology (2019) Vol. 62, Iss. 4, pp. 823-834
Closed Access | Times Cited: 16
Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study
Alessandra Mangia, Francesco Scaglione, Pierluigi Toniutto, et al.
International Journal of Environmental Research and Public Health (2021) Vol. 18, Iss. 13, pp. 7144-7144
Open Access | Times Cited: 14
Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV)
Sandra Abdul Massih, Ahizechukwu C. Eke
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 11, pp. 1413-1424
Open Access | Times Cited: 6
Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study
Jung Wha Chung, Hwa Young Choi, Moran Ki, et al.
Gut and Liver (2020) Vol. 15, Iss. 2, pp. 295-306
Open Access | Times Cited: 8
The Use of Hepatitis C Virus–Positive Organs in Hepatitis C Virus–Negative Recipients
Christian Kuntzen, Zohaib Bagha
Clinics in Liver Disease (2022) Vol. 26, Iss. 2, pp. 291-312
Closed Access | Times Cited: 5
Hepatitis C and Treatment in Patients with Chronic Kidney Disease
Abhijay Jalota, Brian K. Lindner, Beje Thomas, et al.
Disease-a-Month (2020) Vol. 67, Iss. 2, pp. 101017-101017
Closed Access | Times Cited: 7
Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C
Kuo‐Chih Tseng, Meng‐Hsuan Kuo, Chih‐Wei Tseng, et al.
Tzu Chi Medical Journal (2020) Vol. 32, Iss. 4, pp. 331-331
Open Access | Times Cited: 6
Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature
Ivana Mikolašević, Tajana Filipec Kanižaj, Dorotea Božić, et al.
Current Drug Metabolism (2020) Vol. 22, Iss. 2, pp. 89-98
Closed Access | Times Cited: 4
Effect of carvedilol on pharmacokinetics of sofosbuvir and its metabolite GS-331007: role of P-glycoprotein
Salma N Fahmy, Lobna H. Khedr, Sara A. Wahdan, et al.
Journal of Pharmacy and Pharmacology (2024) Vol. 76, Iss. 8, pp. 1051-1064
Closed Access
Compliance on Directly Acting Oral Antiviral in HCV Patients
Parveen Malhotra
Advanced Research in Gastroenterology & Hepatology (2021) Vol. 17, Iss. 1
Open Access | Times Cited: 1
A IMPOSSIBILIDADE DO TRATAMENTO FARMACOLÓGICO PARA HEPATITE C CRÔNICA DEVIDO À INTERAÇÕES MEDICAMENTOSAS
Érica da Silva Anselmo, Ana Paula Schermack, Líncon Bordignon Somensi, et al.
Revista Contemporânea (2023) Vol. 3, Iss. 6, pp. 5665-5684
Open Access
Drug–drug interactions with direct‐acting antivirals: when do we need to care?
Fiona Marra, David Back
(2020), pp. 86-93
Closed Access
Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein
Khaled Abdelkawy, Fathalla Belal, AbdelazizE Abdelaziz, et al.
Drug Research (2022) Vol. 72, Iss. 06, pp. 319-326
Closed Access
Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions
Marina Barakat, Sara Fareed Mohamed Wahdan, Azza S. Awad, et al.
Archives of Pharmaceutical Sciences Ain Shams University (2022) Vol. 6, Iss. 2, pp. 274-291
Open Access
Resource utilization associated with the management of potential interactions between direct-acting antivirals for chronic hepatitis C treatment and cardiovascular and central nervous system drugs
Esther Molina, Marta Torrens, Javier Ampuero, et al.
Economía de la Salud (2022) Vol. 17, pp. 108-119
Open Access
Page 1

Scroll to top